Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer
To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Lung Cancer
DRUG: gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|DRUG: UFT 250mg/m2, daily for 1 year
5 year survival rate
Disease free survival
To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.